Today: 7 February 2026
Subscribe
Browse Category

Biotech Industry News 17 November 2025 - 24 December 2025

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1 Below is what’s driving today’s move, how the market is pricing the deal so far, what Wall Street forecasts looked like before the announcement, and the key dates and risks investors
24 December 2025
······
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen Inc. (NASDAQ: BIIB) is in focus on Monday, December 22, 2025—a day that combines company-specific clinical headlines with a major index event for the stock. Investors are weighing fresh long‑term data for QALSODY (tofersen) in a rare genetic form of ALS, Biogen’s public statement honoring co‑founder Charles Weissmann, and the market mechanics of Biogen’s removal from the Nasdaq‑100, which becomes effective today. At the same time, Wall Street’s outlook remains mixed but active: recent analyst notes span “Reduce/Hold” to “Outperform” with price targets stretching from the low‑$140s to above $200, reflecting a debate over how quickly newer products—especially Leqembi
22 December 2025
·····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the latest available trade on Dec. 22, FOLD is around $14.22, with the market effectively pricing in the probability, timing, and risk of the merger closing—rather than the stand-alone upside of Amicus’ rare disease commercial portfolio. Below is a detailed roundup of the current news, forecasts, and analyst/market commentary shaping Amicus stock on 22.12.2025—and the specific catalysts that can still move
22 December 2025
······
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat+1 The timing isn’t subtle: Zenas is approaching a pivotal clinical-data moment for its lead asset obexelimab, and Wall Street research desks are increasingly framing the stock as a near-term catalyst setup—high potential reward, high potential whiplash. Below is a full roundup of the news,
22 December 2025
·····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts. The reason is simple: on December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per share in cash, valuing Amicus at about $4.8 billion. SEC+1 With U.S. markets closed this weekend, the last meaningful read is Friday’s action: Market data services show Amicus closing around $14.20 on Dec. 19, with trading also widely reported near
21 December 2025
······
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus from traditional biotech catalysts (quarterly launches, pipeline readouts, reimbursement updates) to merger timing, regulatory approvals, and closing risk. SEC+1 As of the latest available pricing around Dec. 20, 2025 (UTC), Amicus shares were trading around $14.18, after a sharp, deal-driven
21 December 2025
·····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters+1 Because it’s a cash buyout, the story for Amicus stock is now less about “quarterly beats” and more about a single question: Will the deal close on time and on the stated terms? And that question—plus a few spicy subplots like patent litigation
20 December 2025
·····
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

December 18, 2025 — Merck & Company, Inc. (NYSE: MRK) is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two pipeline assets, and new Phase 3 momentum for the company’s blockbuster oncology franchise in earlier‑stage bladder cancer. Merck shares traded around $101 intraday on Thursday, reflecting a modest gain versus the prior close, as markets absorbed a busy stream of pharma catalysts and analyst commentary. StockAnalysis Below is a comprehensive, publication‑ready roundup of the key news, forecasts, and analyses dated
18 December 2025
·····
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics Inc. (NASDAQ: SMMT) continues to trade like a classic high-beta biotech: big promises in lung cancer, plenty of red flags, and a stock price stuck near the lower end of its 52-week range while analysts project eye-popping upside. As of the latest US session on December 9, 2025, SMMT is trading around $17–18 per share, versus a 52-week range of $15.55 to $36.91. That means the stock is much closer to its lows than its highs, despite a steady drumbeat of bullish analyst targets and positive trial headlines. Yahoo Finance+1 Below is a rundown of the most current
9 December 2025
·····
Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Published: 8 December 2025 – all data and news current to this date. This article is informational only and not investment advice. Key takeaways Where Moderna stock stands today As of 8 December 2025, Moderna shares trade around $27.70, roughly flat after a powerful rebound that saw the stock jump 8–9% on 5 December on heavy volume. StockInvest+1 Over the last year the stock has: The result is a mid‑cap biotech with: On pure price action, MRNA is still in a long, downward trend from its pandemic peak, but the last few weeks have featured: This volatility is being driven
8 December 2025
·····
Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron stock snapshot on 2 December 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading around $742 per share in late U.S. trading on December 2, 2025, after moving between roughly $731 and $749 during the session and opening close to $742. StockAnalysis Key valuation and trading metrics: Over the past month, REGN has rallied sharply. Zacks notes the stock has gained about 21.5% in a month, while a fresh Simply Wall St piece highlights a 15.1% 30‑day return and 33% gain over 90 days, framing a powerful rebound from earlier weakness. Zacks+1 Today’s headline drivers: gene‑editing deal and the Eylea
2 December 2025
··
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. (NASDAQ: RPTX) is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right (CVR) structure that could unlock additional upside over the coming decade. Repare Therapeutics+1 As of this afternoon’s session, RPTX is changing hands around the low‑$2 range, not far above the estimated US$1.82 per‑share cash consideration embedded in the deal, and up close to 30% versus pre‑announcement levels, reflecting a classic
17 November 2025
·····
1 2 3 4

Stock Market Today

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

7 February 2026
Nvidia surged 7.8% Friday, leading a chip stock rally that pushed the Dow above 50,000 for the first time. The PHLX semiconductor index gained 5.7% as Advanced Micro Devices rose 8.3% and Broadcom 7.1%. Amazon fell 5.6% after projecting $200 billion in 2026 capital spending. Investors weighed a $600 billion AI infrastructure outlay against sharp losses in software shares.
Go toTop